FDA Approves Supplemental Application for Janumet XR
The FDA has approved a supplemental application for Janumet XR, a combination of metformin hydrochloride and sitagliptin phosphate, submitted by Merck.
Asset / Drug
Drug and asset intelligence for Jardiance with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Combination Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.